Home > Expanded Access > Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Loxo Oncology, Inc.

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Official Title: 
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Brief Summary: 
Expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.
Detailed Description: 

N/A for expanded access

Available
EA Type
Individual Patients
Treatment IND/Protocol
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration

Drug: LOXO-292
Open-label expanded access

Eligibility Criteria: 

Inclusion Criteria:

- Diagnosis of cancer with RET activation, who are not eligible for an ongoing LOXO-292 clinical trial and are medically suitable for treatment with LOXO-292

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor

Eligibility Gender: 
All
Contacts: 

Patient Advocacy
855-RET-4-292 (855-738-4292)
clinicaltrials@loxooncology.com

Jen Kherani, MD
Study Director
Loxo Oncology

Loxo Oncology, Inc.
Eli Lilly and Company
EA Number: 
MeSH Terms: 
Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Thyroid Cancer, Papillary, Carcinoma, Neuroendocrine
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.